MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

ESTIMATED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024

This announcement is made by MicroPort Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform holders of the shares and securities of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated financial statements of the Group and the information currently available, for the twelve months ended 31 December 2024 (the "**Reporting Period**"), despite facing a rapidly changing and increasingly complex external environment, especially the introduction of industry policies and changes in the market environment in the second half of 2024, the revenue of the Group is still expected to be achieved a growth of nearly 10% (such revenue growth rate and the revenue growth rate stated in this announcement have excluded the impact of exchange rates) and to record a net loss of no more than US$275 million, representing a narrowing of over 58% as compared to the same period in last year.

The significant narrowing in the expected loss above is mainly attributable to the following factors:

(i) Although the introduction of industry policies and changes in the market environment put pressure on the revenue growth rate of the Group in the second half of the year, the revenue of the Group still recorded a growth of nearly 10% during the Reporting Period. In particular, by leveraging the synergy and allocation advantages of the existing global platform of the Group, the revenue from going-abroad business of the Group increased by approximately 80% year-on-year.

(ii) Active promotion and implementation of resource prioritization initiatives and cost optimisation measures adopted by the Group, resulted in an improvement in the operational efficiency, the ratio of operating expense to revenue of the Group during the Reporting Period decreased by approximately 28 percentage points year-on-year.

(iii) Successful divestment of several non-core businesses during the Reporting Period brought positive gains to the Group.

Based on years of accumulated innovation, during the Reporting Period, the Group and its associates had a total of 6 products admitted in the National Innovative Medical Device Special Review and Approval Procedure (the "**Green Path**"), reaching a total of 36 Green Path products, and ranking first in the medical device industry for ten consecutive years. At the same time, the Group and its associates had a total of 46 Class III medical devices initial registration certificates from the National Medical Products Administration; and obtained 184 initial registration certificates in 43 overseas markets (countries and regions). Among them, 14 products have obtained the CE Mark and 3 products have obtained FDA registration license, which further enriched the domestic and international product portfolio of the Group and accumulated a rich reserve for the Group to achieve higher performance target in the future.

In the future, the Group will continue to leverage its diverse commercial capabilities and advantages of its going-abroad platform, continue to consolidate and deepen various initiatives to improve profitability as well as to promote the optimization and disposal of loss-making businesses and non-core businesses, striving to achieve various important nodes in the turnaround from loss to profit, and continuously enhancing the health of financial statements.

As at the date of this announcement, the Company is still in the process of preparing and completing the annual results of the Group for the twelve months ended 31 December 2024 (the "**2024 Annual Results**"). The information contained in this announcement is based on a preliminary assessment of the business operation information currently available to the Board and is not based on any financial information or information which have been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the shares and securities and potential investors of the Company are advised to carefully read the Company's announcement for the 2024 Annual Results, which is expected to be published by the end of March 2025. Holders of the shares and securities and potential investors of the Company are advised to exercise caution when dealing in the shares and securities of the Company.

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 7 March 2025

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*